Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612285 · ClinicalTrials.gov registry record · Phase 2
Study of SNX-5422 in TP53 Null Cancers
A Phase 2 study, sponsored by Esanex.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02612285 is a Phase 2 study that was terminated before completion, run by Esanex. The registered enrollment target is 1 participants.
The verdict
NCT02612285, a Phase 2 study, was terminated before completion, sponsored by Esanex.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
SNX-5422 is a pro-drug of SNX-2112, a potent, highly selective, small-molecule inhibitor of the molecular chaperone heat shock protein 90 (Hsp90). Initial in vitro evidence supports that SNX-5422 may be active against TP53 null tumors irrespective of tumor type .
Interventions
- DRUG SNX-5422
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02612285
The ClinicalTrials.gov registry entry for NCT02612285 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Esanex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNX-5422 is the first listed.
NCT02612285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02612285 about?
NCT02612285 is a clinical study titled "Study of SNX-5422 in TP53 Null Cancers". SNX-5422 is a pro-drug of SNX-2112, a potent, highly selective, small-molecule inhibitor of the molecular chaperone heat shock protein 90 (Hsp90). Initial in vitro evidence supports that SNX-5422 may be active against TP53 null tumors irrespective of tumor type .
What is the current status of trial NCT02612285?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-03. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02612285?
The interventions under investigation include: SNX-5422 (DRUG).
Who is sponsoring clinical trial NCT02612285?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.